<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670576</url>
  </required_header>
  <id_info>
    <org_study_id>18014</org_study_id>
    <nct_id>NCT03670576</nct_id>
  </id_info>
  <brief_title>It's Not JUST Idiopathic Pulmonary Fibrosis Study</brief_title>
  <acronym>INJUSTIS</acronym>
  <official_title>It's Not JUST Idiopathic Pulmonary Fibrosis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of progression of fibrosis in ILD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall aims of this study are

        -  Identify biomarkers and gene expression profiles that determine progressive fibrotic
           lung disease regardless of aetiology

        -  To prospectively assess biomarkers which predict progressive fibrosis in patients with
           fibrosing lung disease of alternate aetiology, including RA-UIP, Asbestosis, Chronic
           Hypersensitivity Pneumonitis and Unclassifiable fibrotic lung disease

        -  Investigate genetic associations and epigenetic modifications which affect fibrotic
           disease severity and progression

        -  Prospectively evaluate longitudinal disease behaviour in patients with non IPF-fibrotic
           lung diseases with a view to developing composite clinical end-points for subsequent use
           in intervention studies in patients
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study stopped due to COVID-19 Pandemic
  </why_stopped>
  <start_date type="Actual">November 11, 2018</start_date>
  <completion_date type="Anticipated">November 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Defined as &gt;10% relative decline in FVC and mortality at 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>10 years</time_frame>
    <description>All patients will be tagged at the central NHS registry in order to provide mortality data. For this reason we will need to keep our datasets active for up to 10 years to allow a complete mortality analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum and Plasma Biomarkers</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months</time_frame>
    <description>SPD, MUC16, CA199, Nordic Neoepitopes</description>
  </secondary_outcome>
  <other_outcome>
    <measure>DLco</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months</time_frame>
    <description>Diffusing Capacity of the Lung for Carbon Monoxide</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>Baseline, 3 months, 12 months, 24 months.</time_frame>
    <description>Assessment of how the patients well-being may be affected over time by their interstitial lung disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Domicillary Spirometry</measure>
    <time_frame>Daily for the first 3 months of study</time_frame>
    <description>Predicting disease progression and survival</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Optional Bronchoscopy</intervention_name>
    <description>Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <description>MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Samples for Biomarkers</intervention_name>
    <description>a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Home Hand Held Spirometry</intervention_name>
    <description>Patients possessing a smart phone can download an app and are given a small hand held device to record their own spirometry at home. This is for the first three months on study. this is optional.</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (Serum, Plasma) Bronchoscopy Biopsy Samples (Optional)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from ILD and IPF clinics.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male or female aged â‰¥ 18 years old

          -  Able and willing to give written informed consent

          -  Recently diagnosed [defined as diagnostic CT scan or surgical lung biopsy (if
             applicable) &gt;1st May 2017]

          -  An MDT diagnosis of fibrotic interstitial lung disease (reticulation, traction +/-
             honeycombing)

        Sub Groups

          -  Rheumatoid arthritis (rheumatologist diagnosed with anti-CCP antibodies and/or
             Rheumatoid Factor positive)

          -  Asbestosis (appropriate occupational history and radiological evidence of asbestos
             exposure)

          -  Chronic HP in accordance with consensus criteria (appropriate exposure history,
             radiological features +/- avian and fungal precipitins)

          -  Unclassifiable fibrotic lung disease (fibrotic lung disease otherwise unclassifiable
             despite extensive clinical and radiological examination)

          -  IPF in accordance with consensus criteria (ATS/ERS/JRS/ALAT guidelines) as controls

        Exclusion Criteria:

          -  Participating in an interventional clinic trial

          -  Asymptomatic Interstitial Lung Abnormalities (ILA) and normal lung function.

          -  Change in clinical phenotype from initial radiological diagnosis to screening

          -  Acute Hypersensitivity Pneumonitis.

          -  Participants who do not possess a smartphone cannot partake in the domiciliary
             spirometry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Queens Hospital Burton</name>
      <address>
        <city>Burton on Trent</city>
        <state>Derbyshire</state>
        <zip>DE15 0RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings Mill Hospital</name>
      <address>
        <city>Mansfield</city>
        <state>Nottingham</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southmead Hospital North Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medway Maritime Hospital</name>
      <address>
        <city>Gillingham</city>
        <zip>ME7 5NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Manchester General Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Tyneside District Hospital</name>
      <address>
        <city>South Shields</city>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Albert and Edward Infirmary</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcestershire Royal Hospital</name>
      <address>
        <city>Worcester</city>
        <zip>WR5 1DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

